They’re turning their backs on a technology thought to have saved millions of lives—with the potential to save many more.

A well-connected drug company and Laura Loomer wanted Kennedy ally Vinay Prasad gone. Trump Chief of Staff Susie Wiles got ...

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

DelveInsight projects strong NMOSD market growth in the 7MM through 2032, fueled by disease-modifying therapies and key ...

UBS analyst Ashwani Verma raised the firm’s price target on United Therapeutics (UTHR) to $415 from $385 and keeps a Buy rating on the shares. UBS ...

As RL-007 progresses through late-stage clinical development, it represents a significant advancement in schizophrenia ...

D Systems Corporation (NYSE:DDD) announced today its financial results for the second quarter ended June 30, 2025. Revenue of $95 million led by double-digit ...

WASHINGTON, DC – Dr. Vinay Prasad has been reinstated to a senior position at the Food and Drug Administration, according to ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class ...